BRCA
  • About Us
  • Resources
  • News
  • Contact
  • Privacy Policy

FDA approves talazoparib with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer

Posted OnAugust 29, 2023 byPriscilla Kennedy

On June 20, 2023, the Food and Drug Administration approved talazoparib (Talzenna, Pfizer, Inc.) with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).

 

Read the Complete Article Here
Previous Post2023 Grant Recipients
Next PostFDA approves niraparib and abiraterone acetate plus prednisone for BRCA-mutated metastatic castration-resistant prostate cancer
  • Facebook Twitter Linkedin Instagram
    • About Us
    • Press
    • Resources
    • News
    • Privacy Policy
  • Contact
  • © 2022 BRCA | Website by Mosaic